status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).alprazolamalprazolam and trifluoperazine both increase sedation. Use Caution/Monitor.amifampridinetrifluoperazine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amisulpridetrifluoperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.amitriptylinetrifluoperazine and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and trifluoperazine both increase sedation. Use Caution/Monitor.amoxapinetrifluoperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.trifluoperazine and amoxapine both increase sedation. Use Caution/Monitor.anagrelideanagrelide and trifluoperazine both decrease QTc interval. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.anticholinergic/sedative combos decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.apomorphinetrifluoperazine and apomorphine both increase sedation. Use Caution/Monitor.arformoteroltrifluoperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazolearipiprazole and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and trifluoperazine both increase sedation. Use Caution/Monitor.armodafiniltrifluoperazine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.asenapineasenapine and trifluoperazine both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and trifluoperazine both increase sedation. Use Caution/Monitor.atracuriumatracurium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atracurium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineatropine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IMtrifluoperazine increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IM decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine IV/IM decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.avapritinibavapritinib and trifluoperazine both increase sedation. Use Caution/Monitor.azelastineazelastine and trifluoperazine both increase sedation. Use Caution/Monitor.azithromycintrifluoperazine and azithromycin both increase QTc interval. Use Caution/Monitor.baclofenbaclofen and trifluoperazine both increase sedation. Use Caution/Monitor.belladonna alkaloidsbelladonna alkaloids decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna alkaloids decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumbelladonna and opium and trifluoperazine both increase sedation. Use Caution/Monitor.belladonna and opium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna and opium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benperidolbenperidol and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.benperidol and trifluoperazine both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and trifluoperazine both increase sedation. Use Caution/Monitor.benzphetaminetrifluoperazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, benzphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.benztropinetrifluoperazine increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .brexanolonebrexanolone, trifluoperazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and trifluoperazine both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and trifluoperazine both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and trifluoperazine both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphine and trifluoperazine both decrease QTc interval. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and trifluoperazine both decrease QTc interval. Use Caution/Monitor.buprenorphine subdermal implant and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and trifluoperazine both decrease QTc interval. Use Caution/Monitor.buprenorphine transdermal and trifluoperazine both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectiontrifluoperazine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.buprenorphine, long-acting injection and trifluoperazine both decrease QTc interval. Use Caution/Monitor.buprenorphine, long-acting injection and trifluoperazine both increase sedation. Use Caution/Monitor.bupropionbupropion will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.butabarbitalbutabarbital and trifluoperazine both increase sedation. Use Caution/Monitor.butalbitalbutalbital and trifluoperazine both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and trifluoperazine both increase sedation. Use Caution/Monitor.caffeinetrifluoperazine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.cannabidiolcannabidiol, trifluoperazine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition with the coadministration of CYP1A2 substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate.carbinoxaminecarbinoxamine and trifluoperazine both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and trifluoperazine both increase sedation. Use Caution/Monitor.cenobamatecenobamate, trifluoperazine. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratechloral hydrate and trifluoperazine both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and trifluoperazine both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and trifluoperazine both increase sedation. Use Caution/Monitor.chlorzoxazonechlorzoxazone and trifluoperazine both increase sedation. Use Caution/Monitor.cigarette smokingcigarette smoking decreases levels of trifluoperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.cinnarizinecinnarizine and trifluoperazine both increase sedation. Use Caution/Monitor.cisatracuriumcisatracurium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.clemastineclemastine and trifluoperazine both increase sedation. Use Caution/Monitor.clomipraminetrifluoperazine and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and trifluoperazine both increase sedation. Use Caution/Monitor.clonidineclonidine, trifluoperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and trifluoperazine both increase sedation. Use Caution/Monitor.clozapineclozapine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.clozapine and trifluoperazine both increase sedation. Use Caution/Monitor.codeinecodeine and trifluoperazine both increase sedation. Use Caution/Monitor.cyclizinecyclizine and trifluoperazine both increase sedation. Use Caution/Monitor.cyclizine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclizine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclobenzaprinecyclobenzaprine and trifluoperazine both increase sedation. Use Caution/Monitor.cyclobenzaprine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclobenzaprine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyproheptadinecyproheptadine and trifluoperazine both increase sedation. Use Caution/Monitor.dantrolenedantrolene and trifluoperazine both increase sedation. Use Caution/Monitor.daridorexanttrifluoperazine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.darifenacin decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.dasatinibtrifluoperazine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.desfluranedesflurane and trifluoperazine both increase sedation. Use Caution/Monitor.desflurane and trifluoperazine both decrease QTc interval. Use Caution/Monitor.desipraminetrifluoperazine and desipramine both increase sedation. Use Caution/Monitor.desvenlafaxinedesvenlafaxine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mgdeutetrabenazinetrifluoperazine and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.trifluoperazine and deutetrabenazine both increase sedation. Use Caution/Monitor.deutetrabenazine and trifluoperazine both decrease QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.dexfenfluraminetrifluoperazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, dexfenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dexmedetomidinedexmedetomidine and trifluoperazine both increase sedation. Use Caution/Monitor.dexmethylphenidatetrifluoperazine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dextroamphetaminetrifluoperazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, dextroamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dextromethorphandextromethorphan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dextromoramidedextromoramide and trifluoperazine both increase sedation. Use Caution/Monitor.diamorphinediamorphine and trifluoperazine both increase sedation. Use Caution/Monitor.diazepamdiazepam and trifluoperazine both increase sedation. Use Caution/Monitor.dicyclominedicyclomine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.dicyclomine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diethylpropiontrifluoperazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, diethylpropion. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.difelikefalindifelikefalin and trifluoperazine both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and trifluoperazine both increase sedation. Use Caution/Monitor.dihydroergotaminedihydroergotamine, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dimenhydrinatedimenhydrinate and trifluoperazine both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and trifluoperazine both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.diphenhydramine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diphenoxylate hcldiphenoxylate hcl and trifluoperazine both increase sedation. Use Caution/Monitor.dipipanonedipipanone and trifluoperazine both increase sedation. Use Caution/Monitor.dobutaminetrifluoperazine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, dobutamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dolasetrontrifluoperazine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezildonepezil and trifluoperazine both decrease QTc interval. Use Caution/Monitor.donepezil transdermaldonepezil transdermal, trifluoperazine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dopaminetrifluoperazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dopexaminetrifluoperazine increases and dopexamine decreases sedation. Effect of interaction